UroGen Pharma annual return on equity
2016
2017
2018
2019
2020
2021
UroGen Pharma Return on Equity (ROE) Growth & History (URGN)
UroGen Pharma's return on equity was −211.55% for fiscal 2021.
View full UroGen Pharma company overviewUroGen Pharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2021 | 2021-12-31 | −211.55% | −118.67 pp |
| 2020 | 2020-12-31 | −92.88% | −15.11 pp |
| 2019 | 2019-12-31 | −77.77% | +17.63 pp |
| 2018 | 2018-12-31 | −95.40% | −48.24 pp |
| 2017 | 2017-12-31 | −47.16% | −35.25 pp |
| 2016 | 2016-12-31 | −11.91% | — |
UroGen Pharma quarterly return on equity
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q3.24
Q4.24
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −448.92% | — |
| Q3 2024 | 2024-09-30 | −84.81% | — |
| Q4 2021 | 2021-12-31 | −142.44% | −114.29 pp |
| Q3 2021 | 2021-09-30 | −68.81% | −46.91 pp |
| Q2 2021 | 2021-06-30 | −39.50% | −18.11 pp |
| Q1 2021 | 2021-03-31 | −30.01% | −7.16 pp |
| Q4 2020 | 2020-12-31 | −28.15% | −8.23 pp |
| Q3 2020 | 2020-09-30 | −21.90% | −11.68 pp |
| Q2 2020 | 2020-06-30 | −21.39% | −11.71 pp |
| Q1 2020 | 2020-03-31 | −22.85% | −9.84 pp |
| Q4 2019 | 2019-12-31 | −19.92% | +4.57 pp |
| Q3 2019 | 2019-09-30 | −10.21% | +8.70 pp |
| Q2 2019 | 2019-06-30 | −9.68% | +5.50 pp |
| Q1 2019 | 2019-03-31 | −13.01% | +0.90 pp |
| Q4 2018 | 2018-12-31 | −24.49% | −0.71 pp |
| Q3 2018 | 2018-09-30 | −18.91% | — |
| Q2 2018 | 2018-06-30 | −15.19% | — |
| Q1 2018 | 2018-03-31 | −13.91% | — |
| Q4 2017 | 2017-12-31 | −23.78% | — |
UroGen Pharma return on equity trends
Over the last five fiscal years, UroGen Pharma's return on equity decreased from −11.91% to −211.55%, a change of −199.64 percentage points. The latest reported quarter, Q4 2024, shows −448.92%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review UroGen Pharma source filings ↗